Merck announced that the U.S. FDA has approved sotatercept-csrk for the treatment of adults with pulmonary arterial hypertension to increase exercise capacity, improve WHO functional class, and reduce the risk of clinical worsening events. WINREVAIR was previously granted Breakthrough Therapy Designation by the FDA. WINREVAIR is the first FDA-approved activin signaling inhibitor therapy for PAH, representing a new class of therapy that works by improving the balance between pro- and anti-proliferative signaling to regulate vascular cell proliferation underlying PAH.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on MRK:
- Summit Therapeutics initiated with a Buy at Stifel
- Merck: Phase 3 KEYLYNK-006 trial did not meet dual primary endpoints
- Merck: V116 vaccine for pneumococcal diseases show adult immune response
- Buy/Sell: Wall Street’s top 10 stock calls this week
- Merck call volume above normal and directionally bullish